AI Assistant
Blog
Pricing
Log In
Sign Up
T-DM1 ± Pertuzumab als First-line-Option in der Phase-III-Prüfung: MARIANNE-Studie beim HER2-positiven Mammakarzinom
Details
Cite
Export
Add to List
The content you want is available to Zendy users.
Already have an account? Click
here.
to sign in.
